Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVG-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Oxford Science Enterprises
Deal Size : Undisclosed
Deal Type : Financing
AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders
Details : The financing will enable AlveoGene to fast-track the development of its first candidate AVG-001, a novel, inhaled gene therapy designed to promote localised production of alpha-1 antitrypsin to treat patients with Alpha-1 Antitrypsin Deficiency (AATD).
Product Name : AVG-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : AVG-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Oxford Science Enterprises
Deal Size : Undisclosed
Deal Type : Financing